Qube Research & Technologies (QRT)
NRSN icon

Qube Research & Technologies (QRT)’s NeuroSense Therapeutics NRSN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-54
Closed -$60 – 3859
2024
Q2 		$60 Hold
54
– – ﹤0.01% 3485
2024
Q1 		$98 Hold
54
– – ﹤0.01% 4180
2023
Q4 		$42 Buy
+54
New +$36 ﹤0.01% 4082

Other funds holding NRSN

CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NRSN Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of NeuroSense Therapeutics (NRSN) in Q3 2024, closing a stake of 54 shares — an estimated $60 sold.

Qube Research & Technologies (QRT) first reported a position in NRSN in Q4 2023 and held it in 3 quarters. The position peaked at $98 in Q1 2024. 7 funds tracked by Wall St. Rank hold NRSN as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining NeuroSense Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 54 NeuroSense Therapeutics shares in Q3 2024, an estimated $60.
  • Qube Research & Technologies (QRT) first reported a position in NeuroSense Therapeutics in Q4 2023 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s NeuroSense Therapeutics position peaked at $98 in Q1 2024.
  • 7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.